Liposomal NAD+ for the Brain: The Absorption Reality

"Liposomal" is the word that's supposed to fix the whole problem. NAD+ pills, the pitch goes, get destroyed in your gut — so wrap the molecule in a tiny fat bubble, a liposome, and it slips past digestion, gets absorbed intact, and reaches your brain to clear the fog. It's a tidy story with real chemistry behind it. But the honest question isn't whether liposomes are clever packaging; it's whether liposomal NAD+ has been shown to be better absorbed in people, and whether any of that translates into clearer thinking. On both counts, the marketing is far ahead of the evidence.

The bottom line up front

No human trial has shown that liposomal NAD+ improves cognition, focus, or brain fog — and the absorption advantage that's supposed to justify it has not been demonstrated in people either. The strongest data for a liposomal NAD+ formulation comes from a 2025 study in human cells and skin explants, not from anyone swallowing a capsule¹. That study is genuinely interesting, but it tells you nothing about whether the product reaches your bloodstream after an oral dose, let alone your brain. So a liposomal-NAD+ supplement sold "for the brain" is layering one unproven claim (better oral absorption) on top of another (cognitive benefit) — and neither has the human trial to back it.

That's the discipline we hold across this site: separate the mechanism from the human result, and rule in the real, treatable causes of foggy thinking before reaching for any formulation. Start there — see What Actually Causes Brain Fog?.

What "liposomal" actually does — and doesn't

A liposome is a microscopic sphere with a fatty (lipid) shell, the same kind of bilayer your own cell membranes are made of. The idea is that wrapping a fragile, water-loving molecule in a fat coat protects it from stomach acid and digestive enzymes and helps it cross the gut wall. For some compounds, this approach genuinely improves bioavailability. It is a legitimate pharmaceutical strategy, not snake oil.

But "legitimate strategy" and "proven for this product" are different sentences. [[figure:1]]

Three honest caveats matter for NAD+ specifically:

• •The headline study is in cells, not people. In the 2025 paper, a liposomal NAD+ formulation raised intracellular NAD+ and improved survival in cultured human aortic endothelial cells, and reduced markers of cellular aging — but the work was done in cell cultures and ex-vivo skin, and the authors are explicit that "low bioavailability and stability of NAD+ formulations are the main factors limiting its effectiveness"¹. That's the problem the liposome is trying to solve, stated by the researchers themselves. A promising cell result is not evidence of oral absorption in a living person.
• •"Liposomal" on a label is not a regulated guarantee. Whether a given supplement's particles are truly liposomal, stable on the shelf, and intact by the time you swallow them is rarely verified in independent human testing. The word describes an intended technology, not a confirmed delivery outcome for that specific product.
• •Even perfect absorption wouldn't settle the brain question. Getting more NAD+ into your blood is upstream of the thing you actually care about. The molecule still has to do something useful for cognition once it's there — and as we'll see, that's exactly where the human trials fall down.

Plain NAD+ precursors are already absorbed — which undercuts the premise

The whole "pills don't work" framing that sells liposomal products is, at the biomarker level, overstated. Ordinary oral NAD+ precursors are absorbed and reliably raise blood NAD+ without any liposomal wrapper.

An open-label pharmacokinetic study showed that oral nicotinamide riboside (NR) increases the blood NAD+ metabolome in healthy adults in a dose-dependent way². A separate clinical study of oral nicotinamide mononucleotide (NMN) in healthy men found it was safely and efficiently metabolized, with the expected rise in NAD+ metabolites³. These are plain capsules — no liposomes — and they move the marker. So the foundational claim that you need fancy encapsulation just to get NAD+ into your system doesn't hold up for the precursors the human research actually used.

This matters because it reframes what liposomal NAD+ is competing against. The relevant comparison isn't "liposomal vs. nothing." It's "liposomal NAD+ vs. ordinary oral precursors that already raise NAD+ — and that, when tested for thinking, didn't improve it."

Absorption is not efficacy — and here's where it breaks

This is the crux. Suppose, generously, that a liposomal product does get more NAD+ into your blood. The marketing implies that's the win. It isn't. Raising NAD+ and improving cognition are two different outcomes, and the human trials that measured the second one came up empty.

In a randomized placebo-controlled trial of nicotinamide riboside in older adults with mild cognitive impairment, NAD+ rose — and cognition did not improve versus placebo⁴. A 2025 randomized controlled trial in long-COVID, a population defined partly by brain fog, found NR raised NAD+ roughly 3-fold yet delivered no significant benefit for cognition, fatigue, sleep, or mood⁵. A focused review of NR for cognitive impairment reaches the same careful verdict: biologically interesting, not yet shown to protect thinking in people⁶. The marker moved; the experience didn't.

So even granting the liposomal product its best-case absorption story, it lands on the wrong side of the only question that matters. If reliably raising NAD+ with absorbed oral precursors hasn't translated into better cognition in controlled trials, a better-absorbed form of NAD+ inherits the same empty result. The liposome can only change how much NAD+ enters your blood; it can't change what NAD+ does once it's there. We make the same point about infusions in NAD+ IV for Mental Clarity: Is It Worth It?.

And then there's the brain

Even the absorption-to-bloodstream story leaves out the final, hardest barrier: the blood-brain barrier. A "for the brain" claim implicitly asserts that orally dosed NAD+ not only survives digestion and enters the blood, but then crosses into the central nervous system in meaningful amounts and does cognitive work there. There is no human evidence that a liposomal NAD+ supplement clears that bar. The cell-and-skin study that anchors the liposomal claim never tested the brain at all¹, and the oral-precursor trials that did measure cognition found no benefit even when blood NAD+ rose⁴⁵. "It reaches the brain and clears the fog" is a marketing sentence, not a finding. For the broader picture of what NAD+ does and doesn't do for thinking, see our pillar review, NAD+, Brain Fog & Focus: What the Evidence Shows.

Safety and the smarter spend

To be fair on safety: NAD+ precursors have a reasonable tolerability record. A systematic review of NAD-based interventions across clinical conditions found them generally well tolerated, while stressing that the evidence for benefit is inconsistent and the strongest claims outrun the data⁷. High-dose oral NR was generally safe in a randomized trial⁸. Liposomal formulations add fat carriers (often phospholipids) that are themselves food-grade, so the safety worry here is modest. The real cost is the price premium and the opportunity cost — paying extra for "enhanced delivery" of a result that hasn't been demonstrated.

That money and attention have better homes. Sleep is the single best-evidenced lever for attention and a clear mind; reviews of sleep deprivation document dose-dependent cognitive decline⁹. Common, reversible medical causes are routinely missed: thyroid dysfunction independently affects mood and cognition¹⁰, and vitamin B12 deficiency is a classic, correctable cause of fatigue and cognitive slowing¹¹. Among consumables people actually take, omega-3 has the most credible — still modest — general-cognition evidence in adults without dementia¹². None is a miracle. All have more behind them than a liposomal NAD+ capsule.

The honest verdict

Liposomal NAD+ is a real delivery technology wrapped around an unproven brain claim. The best data for a liposomal NAD+ formulation is in cultured cells and skin, not in people; the absorption advantage hasn't been shown for the oral product in humans; ordinary precursors already raise NAD+ without it; and even raising NAD+ — by any route — hasn't improved cognition in the controlled trials that measured it. Add the blood-brain barrier, which a "for the brain" claim quietly assumes is no obstacle, and the gap between the pitch and the evidence is wide. If your goal is a clearer head, the encapsulation isn't the variable that matters. Spend the effort on sleep, a basic medical workup for treatable causes, and honest expectations for anything you swallow — and weigh any cognitive-energy product against that bar with our best cognitive-energy picks.